Project Portfolio

Project Portfolio

New solution for prevention of infection

A molecule to prevent infection caused by gram negative bacteria.

 

A solution to nosocomial infections.

Problema per ser solucionat 
A common problem in patient hospitalizations is the high number of nosocomial infections, many of them caused by Gram-negative bacteria. Furthermore, this problem has been strengthen due to current antibiotic resistances acquired in the last years.
Aplicacions 

The present invention relates to the field of therapeutics and, more in particular, to agents and compositions for the prevention and/or treatment of infections caused by bacteria. But the group is currently working in other applications of interest.

Estat de tecnologia 
The study has shown that removal of anti-Gal antibodies mediated by GAS prevents sepsis and reduces cytokine levels in mice genetically modified so as to express anti-Gal antibodies. It has also been tested successfully in human serum, showing increased bactericidal capacity in GAS-pre-treated serums. Toxicity preclinical studies in house have been performed in primates successfully. IP status: patent ongoing in national phases
Oportunitat de mercat 
Prevention of Gram-negative nosocomial infections will have a positive impact on Hospitals and Healthcare Systems, reducing the hospitalization stage and therefore the costs per patient. Antibiotics are technically inferior, but it is expected that the demand of those may reach 44.68 million dollars in 2016. Since 2015, this market is growing at an annual rate of 6.6% until 2011. GAS914 represents an absolute innovation both concerning the mechanism of action and the effect. It is a soluble inhibitor that can bind and clear antibodies systemically, which is certainly a much better strategy to remove antibodies of the bloodstream than the existing ones.
Context 
Severe sepsis and septic shock are major healthcare problems, affecting millions of individuals around the world each year, killing one in four (and often more), and increasing in incidence. Nosocomial infections affect 5% of patients admitted to hospitals. Anually, this results in 25.000 deaths in Europe and 100.000 in the US. Antibodies may enhance the infective potential of microorganisms instead of being protective to the host. Natural antibodies in normal human serum to a specific cell surface polysaccharide of S. aureus (poly-N-acetyl glucosamine) interfere with the protective antibodies induced by different vaccines against this microorganism causing the failure of immunization. Some strategies have been proposed in the prevention and/or the treatment of infections caused by bacteria in a subject. However, there is still a need in the state of the art to identify suitable and effective agents for use in the treatment or the prevention of infections in a subject caused by bacteria.
Tecnologia 
This study demonstrates that natural antibodies targeting Galactose α1-3 Galactose epitopes (αGal), the most abundant natural antibody in humans, impair infections caused by Gramnegative enteric bacteria. The present invention shows that the removal of antibodies against αGal residues mediated by GAS in a subject increases serum bactericidal activity against gram negative microorganisms. Thus, there is an enhancement of natural immune response to combat the infection by depleting non-neutralizing antibodies from bloodstream.
Technology Readiness Level 
TRL 1
Què busquem? 
Inversió
Inventors 
Máñez R (IDIBELL, HUB)
Patent No. 
EP14382324.3
Priority Date 
22/08/2014

New solution for prevention of infection

Technology Readiness Level 
Què busquem? 
Inversió
Patent No. 
EP14382324.3
Priority Date 
22/08/2014
Punts destacats 
A molecule to prevent infection caused by gram negative bacteria. A solution to nosocomial infections.
Problema per ser solucionat 
A common problem in patient hospitalizations is the high number of nosocomial infections, many of them caused by Gram-negative bacteria. Furthermore, this problem has been strengthen due to current antibiotic resistances acquired in the last years.
Aplicacions 

The present invention relates to the field of therapeutics and, more in particular, to agents and compositions for the prevention and/or treatment of infections caused by bacteria. But the group is currently working in other applications of interest.

Estat de tecnologia 
The study has shown that removal of anti-Gal antibodies mediated by GAS prevents sepsis and reduces cytokine levels in mice genetically modified so as to express anti-Gal antibodies. It has also been tested successfully in human serum, showing increased bactericidal capacity in GAS-pre-treated serums. Toxicity preclinical studies in house have been performed in primates successfully. IP status: patent ongoing in national phases
Oportunitat de mercat 
Prevention of Gram-negative nosocomial infections will have a positive impact on Hospitals and Healthcare Systems, reducing the hospitalization stage and therefore the costs per patient. Antibiotics are technically inferior, but it is expected that the demand of those may reach 44.68 million dollars in 2016. Since 2015, this market is growing at an annual rate of 6.6% until 2011. GAS914 represents an absolute innovation both concerning the mechanism of action and the effect. It is a soluble inhibitor that can bind and clear antibodies systemically, which is certainly a much better strategy to remove antibodies of the bloodstream than the existing ones.
Context 
Severe sepsis and septic shock are major healthcare problems, affecting millions of individuals around the world each year, killing one in four (and often more), and increasing in incidence. Nosocomial infections affect 5% of patients admitted to hospitals. Anually, this results in 25.000 deaths in Europe and 100.000 in the US. Antibodies may enhance the infective potential of microorganisms instead of being protective to the host. Natural antibodies in normal human serum to a specific cell surface polysaccharide of S. aureus (poly-N-acetyl glucosamine) interfere with the protective antibodies induced by different vaccines against this microorganism causing the failure of immunization. Some strategies have been proposed in the prevention and/or the treatment of infections caused by bacteria in a subject. However, there is still a need in the state of the art to identify suitable and effective agents for use in the treatment or the prevention of infections in a subject caused by bacteria.
Tecnologia 
This study demonstrates that natural antibodies targeting Galactose α1-3 Galactose epitopes (αGal), the most abundant natural antibody in humans, impair infections caused by Gramnegative enteric bacteria. The present invention shows that the removal of antibodies against αGal residues mediated by GAS in a subject increases serum bactericidal activity against gram negative microorganisms. Thus, there is an enhancement of natural immune response to combat the infection by depleting non-neutralizing antibodies from bloodstream.